Showing 191-200 of 2745 results for "".
MATV News: New HA Fillers Show Promise; HydraFacial Launches Syndeo; AACS Names New President
https://modernaesthetics.com/series/matv-news/matv-news-new-ha-fillers-show-promise-hydrofacial-launches-syndeo-aacs-names-new-president/33666/New HA fillers from Hallura show promise for lips, nasolabial folds, and cheeks. HydraFacial’s Syndeo aims to enhance the consumer and provider experience; and the American Academy of Cosmetic Surgery introduces J. Kevin Duplechain, MD as its new president.MATV News Extra: AAFPRS 2022 Outlook
https://modernaesthetics.com/series/matv-news/matv-news-extra-aafprs-2022-outlook/33663/Corey S. Maas, MD, President of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), shares his goals for his leadership term. He also discusses the findings of the AAFPRS annual statistics and his insights about what’s driving the current surge in surgical and non-surgical aeMATV News: AAFPRS Annual Statistics; Merz Aesthetics Kicks of New Initiative; Juvéderm Volbella XC Wins Approval for Undereye Hollows
https://modernaesthetics.com/series/matv-news/matv-news-aafprs-annual-statistics-merz-aesthetics-kicks-of-new-initiative-juvederm-volbella-xc-wins-approval-for-undereye-hollows/33662/AAFPRS President Corey S. Maas, MD discusses the association’s latest annual statistics and the surge in demand for facial plastic surgery in 2021; Merz Aesthetics kicks of a new initiative focused on what makes people feel confident; and the FDA approves Allergan Aesthetics’ Juvederm Volbella XC foThe Advisor Advantage: Does Your Advisor Bring These Benefits to Your Portfolio?
https://modernaesthetics.com/ma-issues-index/2022-jan-feb/the-advisor-advantage-does-your-advisor-bring-these-benefits-to-your-portfolio/35136/When it comes to financial planning, choosing the right advisor can make a significant impact.MATV News: Revance Wins FDA Nod For Redensity Filler; Obagi Introduces Skintrinsiq, Aesthetic Physicians Cope with Covid-19
https://modernaesthetics.com/series/matv-news/matv-news-revance-wins-fda-nod-for-redensity-filler-obagi-introduces-skintrinsiq-aesthetic-physicians-cope-with-covid-19/33656/FDA Approves Revance’s RHA Redensity filler for perioral rhytids, Obagi enters the device market with introduction of Skintrinsiq, and aesthetic physicians discuss how they’re coping with the recent COVID-19 surge.MATV News: Sculptra Wins Expanded Label; Cutera Introduces truSculpt flex+, AACS Opens Annual Meeting Registration
https://modernaesthetics.com/series/matv-news/matv-news-sculptra-wins-expanded-label-cutera-introduces-trusculpt-flex-aacs-opens-annual-meeting-registration/33653/Galderma’s Sculptra gets an expanded label, Cutera rolls out its next generation muscle-sculpting device—truSculpt flex+, and the American Academy of Cosmetic Surgery opens registration for its annual meeting.MATV News: Thriving in Diversity; Gryphon Acquisition of Revision; Sun Hero Campaign
https://modernaesthetics.com/series/matv-news/matv-news-thriving-in-diversity-gryphon-acquisition-of-revision-sun-hero-campaign/33651/The Thriving in Aesthetics educational series is back for a second season—Thriving in Diversity. Steve Dayan, MD and Sabrina Fabi, MD preview upcoming episodes. Revision Skincare CEO Maria Carell talks about the company’s next steps after its acquisition by Gryphon, and Amy Brodsky, MD wants you toUp Your ‘App’titude
https://modernaesthetics.com/ma-issues-index/2021-sept-oct/up-your-apptitude/35088/Expert share tips on the best apps for your practice.Are Millennials the Next Frontier of Medical Aesthetics?
https://modernaesthetics.com/ma-issues-index/2021-sept-oct/are-millennials-the-next-frontier-of-medical-aesthetics/35082/The downsides of alienating Boomers to cater to Millennials.The Art of the Eyes
https://modernaesthetics.com/ma-issues-index/2021-sept-oct/the-art-of-the-eyes/35081/One busy practice set itself apart by creating a results-driven, combination eye treatment package that yielded better patient results and high patient satisfaction compared to typical non-surgical eye treatment options.